ClinicalTrials.gg
RecruitingNCT07632742Updated Oct 15, 2026

Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial

An interventional study of Magneto 150 holmium laser and Moses 2.0 holmium laser in Enlarged Prostate (BPH) and Benign Prostatic Hyperplasia, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Northwestern University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 15, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Prostatic Hyperplasia by Northwestern University — 4 open to participants now, 5 under way, none of them phase 3. Prostatic Hyperplasia · Northwestern University.

Started
2026
with 2 others
No phase
7 of 10
3 open now
Registered
10th of 10
by date

Among the 10 studies in Prostatic Hyperplasia by Northwestern University, this one is one of 3 that started in 2026, is one of 7 with no phase, and was the 10th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

4 of the 10 studies in Prostatic Hyperplasia by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Hyperplasia by Northwestern University, or all of them as a file.
02

Study summary

The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.

Read the detailed description

The Magneto 150 is a high-powered 150W holmium laser that offers similar pulse-modulation benefits of MOSES 2.0, which facilitates effective dissection and enucleation of the tissue plane while also offering a new first-of-its kind proprietary Magneto setting which allows for very low peak power of 500W and longer pulse duration which allows for better hemostasis.

03

Conditions studied

  • Enlarged Prostate (BPH)
  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • HoLEP
  • Holmium laser
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms
  • Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)

Exclusion criteria

Exclusion Criteria:

  • Patients who lack decisional capacity
  • Patients unable to read/speak English
  • Patients who are on a blood thinner (anticoagulation medication)
  • Patients who do not have internet access to complete postoperative surveys
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    Moses 2.0

    HoLEP procedure performed using the Moses 2.0 holmium laser

    Device: Moses 2.0 holmium laser

  • Experimental
    Magneto 150

    HoLEP procedure performed using Magneto 150 holmium laser

    Device: Magneto 150 holmium laser

Interventions

  • DeviceMagneto 150 holmium laser

    The HoLEP procedure will be performed using the Quanta Magneto 150 holmium laser

  • DeviceMoses 2.0 holmium laser

    The HoLEP procedure will be performed using the Moses 2.0 holmium laser

06

What researchers measure

Primary outcomes

  1. Mean hemostasis time

    Overall intraoperative hemostasis time

    Time frame: During surgery

Secondary outcomes

  1. Mean (average) enucleation time

    Time taken to surgically remove excess prostate tissue while leaving the shell of the prostate intact and within the body.

    Time frame: During surgery

  2. Total operative time

    Time taken from official procedure start to completion (not accounting for the time that the patient is wheeled in, prepped and out of the operating room).

    Time frame: During surgery

  3. Hemostasis efficiency

    minutes/gram (prostate tissue removed)

    Time frame: During surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.

Of 155 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 13 months is below that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → May 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 8, 2026
StartActual
May 29, 2026was Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→May 29, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Start date Jun 2026→May 29, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07632742
Responsible party
Amy Krambeck (Professor, Northwestern University) — Principal investigator
First posted
Jun 8, 2026
Start date
May 29, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Alyssa McDonald, MPH
Contact
alyssa.mcdonald@northwestern.edu
312-695-8146
Perry Xu, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion